Thematische Bibliographien / Locally advanced cervical cancer

Inhaltsverzeichnis

Zeitschriftenartikel
Dissertationen
Bücher
Buchteile
Konferenzberichte
Berichte der Organisationen

Auswahl der wissenschaftlichen Literatur zum Thema „Locally advanced cervical cancer“

Autor: Grafiati

Veröffentlicht am 29. März 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Locally advanced cervical cancer" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Zeitschriftenartikel zum Thema "Locally advanced cervical cancer"

Manders, Dustin B., Abel Morón, Donald McIntire, David S. Miller, Debra L. Richardson, Siobhan M. Kehoe, Kevin V. Albuquerque und Jayanthi S. Lea. „Locally Advanced Cervical Cancer“. American Journal of Clinical Oncology 41, Nr. 5 (Mai 2018): 447–51. http://dx.doi.org/10.1097/coc.0000000000000300.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Rose, Peter G. „Locally advanced cervical cancer“. Current Opinion in Obstetrics and Gynecology 13, Nr. 1 (Februar 2001): 65–70. http://dx.doi.org/10.1097/00001703-200102000-00010.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Kamrava, Mitchell, und Sushil Beriwal. „Pembrolizumab for locally advanced cervical cancer“. Lancet 404, Nr. 10467 (November 2024): 2049. http://dx.doi.org/10.1016/s0140-6736(24)02228-1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Schmid, Maximilian P., Primoz Petric, Umesh Mahantshetty, Christian Kirisits, Kari Tanderup, Ina Jürgenliemk-Schulz, Jacob Lindegaard und Richard Pötter. „Pembrolizumab for locally advanced cervical cancer“. Lancet 404, Nr. 10467 (November 2024): 2050–51. http://dx.doi.org/10.1016/s0140-6736(24)02231-1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Murakami, Naoya, Noriyuki Okonogi, Yasuhisa Terao und Naoto Shikama. „Pembrolizumab for locally advanced cervical cancer“. Lancet 404, Nr. 10467 (November 2024): 2049–50. http://dx.doi.org/10.1016/s0140-6736(24)02229-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Dong, Binhua, Yong Lu, Yue Wang, Pengming Sun und Huachun Zou. „Pembrolizumab for locally advanced cervical cancer“. Lancet 404, Nr. 10467 (November 2024): 2050. http://dx.doi.org/10.1016/s0140-6736(24)02230-x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Rojas-Espaillat, Luis A., und Peter G. Rose. „Management of locally advanced cervical cancer“. Current Opinion in Oncology 17, Nr. 5 (September 2005): 485–92. http://dx.doi.org/10.1097/01.cco.0000174049.14515.8d.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Petsuksiri, Janjira, Atthapon Jaishuen, Pittayapoom Pattaranutaporn und Yaowalak Chansilpa. „Advanced Imaging Applications for Locally Advanced Cervical Cancer“. Asian Pacific Journal of Cancer Prevention 13, Nr. 5 (30.05.2012): 1713–18. http://dx.doi.org/10.7314/apjcp.2012.13.5.1713.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Trukhacheva, N. G., I. G. Frolova, L. A. Kolomiets, A. V. Usova, E. G. Grigor’ev, S. A. Velichko und O. N. Churuksaeva. „Novel approaches to diagnostic imaging of locally advanced cervical cancer“. Siberian journal of oncology 18, Nr. 2 (26.04.2019): 83–91. http://dx.doi.org/10.21294/1814-4861-2019-18-2-83-91.

Der volle Inhalt der Quelle

Annotation:

Cervical cancer is the second most common cancer after breast cancer and the third most common cause of cancer-related death followed by breast and lung cancers among women worldwide. advances in diagnostic imaging techniques provide better assessment of regional and distant cervical cancer metastasis. the use of contrast-enhanced ultrasound is a revolutionary imaging modality; it has several advantages over ct: no radiation exposure, nephrotoxicity, obtaining real-time information, relatively low cost and ease of use. currently, the contrast agent sonoVue is widely used in ultrasound imaging of liver, kidneys and pancreas lesions, as well as for closed abdominal injuries, multiple organ failure, breast and prostate cancers, etc. However, the role of contrast-enhanced ultrasound in gynecology is not clearly established. one of the most effective tools for the detection of locally advanced cervical cancer is mRi, which is used mainly to determine the local extent of the tumor. However, the use of functional mRitechniques has not yet been included in the standards. cervical cancer tissue has been found to show significantly lower diffusion-weighted imaging (dWi) values than normal cervical tissue, thus facilitating the detection of tumor and its spread. dWiis also used for differentiating changes after biopsy from residual tumor and for identifying small lymph nodes. the pEt/cttechnique combines the metabolic images of pEtwith anatomical images of ctand is more accurate than high resolution ctalone, especially in determining the involvement of regional lymph nodes and distant organs. 18-Fdg-pEt/cthas been successfully used for accurate staging of the disease (especially late stage), assessment of treatment response, radiotherapy planning, and detection of disease progression. in patients with advanced stages of cervical cancer (iiBiV stage), the 18-Fdg-pEt/ ctfindings can determine the treatment strategy in most cases, primarily due to high sensitivity (75–100 %) and specificity (87–100 %) in the detection of lymph node metastases.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Gennigens, Christine, Marjolein De Cuypere, Johanne Hermesse, Frédéric Kridelka und Guy Jerusalem. „Optimal treatment in locally advanced cervical cancer“. Expert Review of Anticancer Therapy 21, Nr. 6 (11.03.2021): 657–71. http://dx.doi.org/10.1080/14737140.2021.1879646.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Dissertationen zum Thema "Locally advanced cervical cancer"

Bhagaloo, Visham. „Volumetric modulated Arc Therapy versus 3D conformal radiotherapy in the treatment of locally advanced cervical cancer. A single institution, comparative dosimetric study“. Master's thesis, Faculty of Health Sciences, 2021. http://hdl.handle.net/11427/32601.

Der volle Inhalt der Quelle

Annotation:

Background: External Beam Radiotherapy is essential in the management of locally advanced cervical cancer (LACC). Generally, VMAT is thought to achieve higher conformity to the Planned Target Volume (PTV) and better sparing of organs at risk (OAR) when compared to 3D-CRT. This study focused on these principles as it applied to treatment and potential toxicity in the management of LACC. Aim: To compare dosimetric parameters between VMAT and 3D-CRT in the management of LACC. Setting: The study analysed patients treated at Groote Schuur Hospital between May and December 2017. Method: A non-randomized comparative retrospective study. EBRT plans for 3D-CRT and VMAT were generated and data on treatment parameters for PTV D50%, Dmax, Dmean, Conformity Index (CI), Homogeneity Index, Treated Volume (TV), Irradiated Volume (IV) and OAR constraints; femoral heads, bladder, bowel bag, rectum and bone marrow were collected. Results: Of the 45 patients assessed, VMAT showed significantly lower treatment parameter values for CI (1.09 vs 1.49; p< .001) whereas, 3D-CRT showed lower Dmax (48.1Gy vs 49.2Gy; p< .001) and rectum (88.5% vs 96%). A reduced 3D-CRT dose was noted for bladder Dmax (47.4Gy vs 48.3Gy; p< .001). Conclusion: VMAT offered a superior dosimetric option, with better OAR dose sparing and optimal tumour dosimetry.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Atalay, Mustafa Can. „Multidrug Resistance In Locally Advanced Breast Cancer“. Phd thesis, METU, 2004. http://etd.lib.metu.edu.tr/upload/12604991/index.pdf.

Der volle Inhalt der Quelle

Annotation:

ABSTRACT MULTIDRUG RESISTANCE IN LOCALLY ADVANCED BREAST CANCER ATALAY, Mustafa Can Ph. D., Department of Biotechnology Supervisor: Prof. Dr. Ufuk GÜ
NDÜ
Z June 2004, 70 pages Breast cancer is the most frequently detected cancer among women. Early diagnosis leads to long term survival when the patients are treated with surgery, radiotherapy, chemotherapy, and hormone therapy. Unfortunately, advanced disease could still be encountered in some patients resulting in a poorer prognosis. The primary treatment modality is chemotherapy for this group of patients. Drug resistance is a serious problem resulting in the use of different drugs during chemotherapy and knowing the possibility of resistance before initiating first line chemotherapy may save time and money, and most importantly, may increase patient&rsquo
s survival. Therefore in this study, multidrug resistance is studied in locally advanced breast cancer patients. The breast tissues obtained from 25 patients both before and after chemotherapy were examined for drug resistance. Reverse transcriptase polymerase chain reaction was used for the detection of mdr1 and mrp1 gene expression. In addition, immunohistochemistry technique was used for P-glycoprotein and MRP1 detection. JSB-1 and QCRL-1 monoclonal antibodies were utilized to detect P-glycoprotein and MRP1, respectively. Five patients were unresponsive to chemotherapy. In four of these patients mdr1 gene expression was induced by chemotherapy where as the fifth patient initially had mdr1 gene expression. In addition, Pgp positivity was detected in 9 patients after chemotherapy. Both the induction of mdr1 gene expression (p<
0.001) and Pgp positivity (p<
0.001) during chemotherapy were significantly related with clinical response. On the other hand, mrp1 gene expression and MRP1 positivity were detected in 68% of the patients before the therapy. After chemotherapy, mrp1 expression increased to 84%. Although 80% of the clinically unresponsive patients had mrp1 gene expression, the relation between mrp1 expression and clinical drug response was not strong. Thus, it can be concluded that in locally advanced breast cancer mdr1 gene expression during chemotherapy contributed to clinical unresponsiveness. However, mrp1 gene expression did not correlate strongly with the clinical response. When RT-PCR and immunohistochemistry methods are compared in terms of detection of drug resistance, it seems that both methods gave similar and reliable results.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Vermaas, Maarten. „Multimodality treatment for locally advanced and recurrent rectal cancer“. [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 2008. http://hdl.handle.net/1765/11997.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Arcelli, Alessandra <1983&gt. „Outcome analysis of predictors in locally advanced pancreatic cancer“. Doctoral thesis, Alma Mater Studiorum - Università di Bologna, 2021. http://amsdottorato.unibo.it/9565/3/arcelli_alessandra_tesi.pdf.

Der volle Inhalt der Quelle

Annotation:

Guidelines report a wide range of options in locally advanced pancreatic cancer (LAPC): definitive chemotherapy or chemoradiotherapy or the emerging stereotactic body radiotherapy (SBRT) (+/- chemotherapy). On behalf of the AIRO (Italian Association of Radiation Oncology and Clinical Oncology) Gastrointestinal Study Group, we collected retrospective clinical data on 419 LAPC from 15 Italian centers. The study protocol (PAULA-1: Pooled Analysis in Unresectable Locally Advanced pancreatic cancer) was approved by institutional review board of S. Orsola-Malpighi Hospital (201/2015/O/OssN). From this large database we performed tree different studies. The first was a retrospective study about 56 LAPC treated with SBRT at a median biologically equivalent dose of 48 Gy +/- chemotherapy. We demonstrated a statistically significant impact of biologically equivalent dose based on an α/β ratio of 10Gy ≥ 48Gy for local control (LC) (p: 0.045) and overall survival (p: 0.042) in LAPC. The second was a retrospective matched-cohort case-control study comparing SBRT (40 patients) and chemoradiation (40 patients) in LAPC in terms of different endpoints. Our findings suggested an equivalence in terms of most outcomes among the two treatments and an advantage of SBRT in terms of LC (p: 0.017). The third study was a retrospective comparison of definitive chemotherapy, chemoradiotherapy and SBRT (+/- chemotherapy) in terms of different outcomes in LAPC. A predictive model for LC in LAPC was also developed reaching an AUC of 68% (CI 58,7%-77,4%). SBRT treatment emerged as a positive predictive factor for improved LC. Findings deriving from our three studies suggest that SBRT is comparable to standard of care (definitive chemotherapy and chemoradiotherapy) in terms of outcomes. SBRT seems to be an emerging therapeutic option in LAPC significantly improving local control. Furthermore, we have shown the potential of a predictive model for LC. Randomized trials are needed to compare these different therapeutic options in LAPC.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Hakenberg, Oliver W., Michael Fröhner und Manfred P. Wirth. „Treatment of Locally Advanced Prostate Cancer – The Case for Radical Prostatectomy“. Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-133798.

Der volle Inhalt der Quelle

Annotation:

The treatment of clinically locally advanced prostate carcinoma (stage cT3) remains controversial. One of the main reasons for this controversy results from the substantial staging error attached to the clinical diagnosis cT3 with overstaged T2 tumors and understaged node-positive cases. Treatment options in this situation include radical prostatectomy, external beam radiotherapy, immediate or delayed androgen deprivation treatment and the so-called ‘watchful waiting’. Acceptable and often surprisingly good tumor-specific survival rates have been reported for radical prostatectomy in pT3 series – based on good clinical case selection – approaching those of pT2 series. In lymph node-positive pT3 cases, adjuvant hormone deprivation seems to prolong survival which it does not in lymph node-negative pT3 disease. A benefit of adjuvant external beam radiotherapy after radical prostatectomy for pT3 cases in prolonging overall survival has not been shown, despite the fact that it can prevent or delay biochemical and local recurrence. External beam radiotherapy as the only treatment for cT3 disease results in unfavorable tumor-specific survival rates, which can be significantly improved with adjuvant hormonal treatment with LHRH agonists. If, in case of advanced age and/or significant comorbidity, primary hormonal treatment is chosen, early hormonal deprivation therapy seems to offer marginal benefits in survival compared to delayed treatment
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Hakenberg, Oliver W., Michael Fröhner und Manfred P. Wirth. „Treatment of Locally Advanced Prostate Cancer – The Case for Radical Prostatectomy“. Karger, 2006. https://tud.qucosa.de/id/qucosa%3A27536.

Der volle Inhalt der Quelle

Annotation:

The treatment of clinically locally advanced prostate carcinoma (stage cT3) remains controversial. One of the main reasons for this controversy results from the substantial staging error attached to the clinical diagnosis cT3 with overstaged T2 tumors and understaged node-positive cases. Treatment options in this situation include radical prostatectomy, external beam radiotherapy, immediate or delayed androgen deprivation treatment and the so-called ‘watchful waiting’. Acceptable and often surprisingly good tumor-specific survival rates have been reported for radical prostatectomy in pT3 series – based on good clinical case selection – approaching those of pT2 series. In lymph node-positive pT3 cases, adjuvant hormone deprivation seems to prolong survival which it does not in lymph node-negative pT3 disease. A benefit of adjuvant external beam radiotherapy after radical prostatectomy for pT3 cases in prolonging overall survival has not been shown, despite the fact that it can prevent or delay biochemical and local recurrence. External beam radiotherapy as the only treatment for cT3 disease results in unfavorable tumor-specific survival rates, which can be significantly improved with adjuvant hormonal treatment with LHRH agonists. If, in case of advanced age and/or significant comorbidity, primary hormonal treatment is chosen, early hormonal deprivation therapy seems to offer marginal benefits in survival compared to delayed treatment.
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Cao, Maria Dung. „MR metabolic characterization of locally advanced breast cancer : – treatment effects and prognosis“. Doctoral thesis, Norges teknisk-naturvitenskapelige universitet, Institutt for sirkulasjon og bildediagnostikk, 2012. http://urn.kb.se/resolve?urn=urn:nbn:no:ntnu:diva-16250.

Der volle Inhalt der Quelle

Annotation:

Brystkreft er den hyppigste kreftsykdommen blant kvinner. Lokalavansert brystkreft utgjør omtrent 10% av alle brystkrefttilfeller og omfatter en heterogen pasientgruppe med ulike prognoser. Pasienter med lokalavansert brystkreft får ofte kjemoterapi før kirurgisk fjerning av tumor, såkalt neoadjuvant kjemoterapi, for å redusere størrelsen på tumoren. Det er stor variasjon i behandlingsrespons for denne pasientgruppen, og det er derfor behov for å utvikle målrettet og individualisert behandling, samt metoder for oppfølging av behandlingsrespons. Metabolomics er en systematisk analyse av småmolekylære forbindelser (metabolitter) i biologiske prøver. Den metabolske profilen til brystkreftvev er vist å korrelere med viktige kliniske parametere, for eksempel tumorgrad, hormonreseptorstatus og lymfeknutespredning. Magnetisk resonans (MR) spektroskopi er en metode som kan gi en detaljert beskrivelse av metabolittprofilen i vevet. En fordel med denne metoden er at vevsprøven er intakt etter analysen slik at den samme vevsprøven kan analyseres videre med andre metoder, for eksempel immunohistokjemi, genuttrykk- eller proteinanalyse. En sentral gruppe metabolitter innenfor brystkreftforskning er kolinforbindelser. Disse metabolittene er viktig for celledeling, signaloverføring, lipidmetabolisme og cellens membranstruktur. Laktat er en annen viktig metabolitt som inngår i energimetabolismen. I dette arbeidet ble vevsprøver fra pasienter med lokalavansert brystkreft analysert ved bruk av MR spektroskopi for prediksjon av behandlingsrespons og overlevelse. I tillegg undersøkte vi rollen til glycerophosphodiester phosphodiesterase (GDPD) i regulering av kolinforbindelser Alle pasienter hadde en effekt av behandlingen som ble gitt, og nesten alle fikk en reduksjon i tumorstørrelse etter behandling. Resultatene viste ingen metabolske forskjeller mellom pasienter med klinisk god eller dårlig behandlingsrespons. Resultatene viser derimot at de metabolske forandringene som skjer under neoadjuvant kjemoterapi er forskjellig i pasienter som overlever mer enn fem år og de som dør før fem år. Høyere nivå av laktat, glycine og kolinforbindelser etter behandling var forbundet med dårlig prognose. Analysene av GDPD5 tyder på at enzymet er involvert i reguleringen av kolinmetabolismen, men dets rolle for bruk i målrettet terapi er fortsatt uklart og nye studier må til for å undersøke dette. MR metabolomics kan brukes til å undersøke metabolske forandringer under neoadjuvant kjemoterapi behandling og kan identifisere viktige metabolitter for prediksjon av overlevelse hos pasienter med lokalavansert brystkreft.
Breast cancer is the most frequent cancer disease among women globally. Locally advanced breast cancer (LABC) constitutes a heterogeneous group of patients with variable prognosis. Today’s treatment decision is predominately based on clinical assessment, histopathological evaluation, and hormone receptor and lymph node status. So far, these data are not sufficient for designing a proper personalized treatment or accurately predicting treatment response and survival. Molecular characterization of tumors may help stratifying patients for individualized treatment, thereby achieving better prognosis. Magnetic resonance (MR) metabolomics analyses assess the downstream products of gene and protein expressions, i.e. the metabolites, and have shown to provide both predictive and prognostic information for several types of cancers. Proton high resolution magic angle spinning (1H HR MAS) MR spectroscopy is a non-destructive and high-throughput technique that provides highly resolved MR spectra from biological tissue. Recently, altered cell metabolism is suggested as a new emerging hallmark of cancer. Choline phospholipid metabolism is involved in cell signaling, lipid metabolism, and the structural integrity of the cell membrane. Several MRS studies have suggested the total choline-containing metabolite (tCho) level as an in vivo biomarker for diagnosis and treatment evaluation of breast cancer. Reprogramming of energy metabolism and activation of tumor hypoxic response are commonly observed in cancers, and can be characterized by high lactate production. In this thesis, multivariate data analyses and metabolite quantification of 1H HR MAS MRS data were performed to investigate the potential of metabolomics for prediction of clinical response and long-term survival in LABC patients receiving neoadjuvant chemotherapy (NAC). In addition, the role of glycerophosphodiester phosphodiesterase (GDPD) in choline phospholipid metabolism of human breast cancer was investigated. All patients had a metabolic response to NAC and almost all patients had a reduction in tumor size. Our results show no clear differences in metabolic responses to NAC between patients with partial response and stable disease and no significant multivariate models for prediction of clinical response by MR metabolomics data. In general, all patients experienced a decrease in tCho levels. It is possible that a cohort including also patients with progressive disease would reveal clearer differences in the metabolite profiles between the clinical response groups. This thesis demonstrates that MR metabolomics contain prognostic information that is associated with survival status of LABC patients. Increase in lactate levels as a response to NAC was associated with low survival rates (< 5 years), while decreased glycine and choline phospholipid metabolites were associated with long-term survival (≥ 5 years). The observed metabolite profiles consisting of higher levels of lactate, glycine, and tCho post-treatment were predictive of low breast cancer survival rates. GDPD5 gene expression was correlated with choline phospholipid metabolite levels and with CHKA and PLD1 gene expressions suggesting GDPD5 to have a role in regulation of choline phospholipid metabolism in human breast cancer. However, more studies are needed to investigate the relationship between GDPD5 and tumor malignancy, and also estrogen receptor status, for use as target in breast cancer treatment. In conclusion, monitoring metabolic responses to NAC by MR metabolomics may have the potential to assist the prediction of survival and help identify new targets for therapeutic treatment of breast cancer.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Silveira, Willian Abraham da. „Genetic profile analysis of tumor stem cells in locally advanced breast cancer“. Universidade de São Paulo, 2015. http://www.teses.usp.br/teses/disponiveis/17/17145/tde-05012016-144854/.

Der volle Inhalt der Quelle

Annotation:

INTRODUCTION: Breast cancer is the most common cancer in women worldwide and metastatic dissemination is the principal factor related to death by this disease. Breast cancer stem cells (bCSC), defined in this work as the ALDH1high/LIN-/ESA+ population, are thought to be responsible for metastasis and chemoresistance. The objective of this work is to find gene master regulators, in particular transcription factors (TFs), which are controlling the bCSC phenotype. METHODS: We used in this work two groups of datasets with transcriptome data, the discovery dataset group contains one dataset obtained by ourselves containing three paired samples comparing the bCSC and the bulk of the tumor (My Data - bCSC/Bulk dataset), a dataset with eight paired samples comparing the bCSC and cancer cells (Wicha - bCSC/CC dataset) and a dataset with 115 samples of breast cancer tissue (clinical response dataset). The second group, validation datasets, contains the BRCA-TCGA dataset with information of 621 samples, 4142 breast cancer samples of the Kmplot tool, 17 primary samples of BasL subtype and their information of grafting in patient derived xenografts and analyzes of cell lines (MF10A and HMLE). For the analyzes we used the paired t-test in the Limma R package, the ARACNE algorithm for the inference of regulons in the clinical response dataset, MRA-FET to define the master regulators of the bCSC phenotype, and GSEA to identify the biological meaning of the findings in the different datasets. RESULTS: We identified 12 TFs as master regulators of the bCSC phenotype, with nine of them forming two highly interconnected networks, one positively related with the bCSC phenotype formed by SNAI2, TWIST, PRRX1, BNC2 and TBX5 with its regulons, defined here as the mesenchymal transcription network and one negative correlated to the phenotype formed by SCML4, ZNF831, SP140 and IKZF3, defined as the immune response transcription network, totally unknown in the context of breast cancer in the literature. Although still with weak evidence, ZEB1 seems to control the two networks and can be responsible for the expression of ALDH1 and of the three remaining TFs: ID4, HOXA5 and TEAD1. As their names portray, our data showed in the different datasets, and independently of the molecular subtype and of the platform used, that the mesenchymal transcription network seems to be responsible for the bCSC phenotype and the immune response transcription network to the adaptive immune response in the tumor and a better prognosis for the patients. We also defined 10 membrane proteins as new markers and/or therapeutic targets of the bCSC. CONCLUSION: We found and described two TF networks that seem to control the bCSC phenotype, one of them totally unknown until now and correlated to a good prognosis. Our findings have a clear potential for clinical use.
INTRODUÇÃO: O cancer de mama é no mundo o câncer mais comum em mulheres e a disseminação metastática é o principal fator relacionado com a morte pela doença. Acreditasse que as células tronco do câncer de mama - bCSC, na sigla em inglês e definida neste trabalho com a população ALDH1high/LIN-/ESA+ - é responsável pela metástase e pela quimioresistência. O objetivo deste trabalho é encontrar genes que são essenciais para o controle do fenótipo das bCSC, em particular fatores de transcrição. MATERIAIS E MÉTODOS: Nesse trabalho nós utlizamos dois grupos de datasets com dados do transcriptoma, o grupo de datasets de descoberta contém um dataset gerado por nós com 3 amostras pareadas comparando as bCSC com o tumor total (My Data - bCSC/Bulk dataset), um dataset com 8 amostras pareadas comparando as bCSC com as células cancerígenas (Wicha - bCSC/CC dataset) e um dataset com 115 amostras de tecido de câncer de mama (Clinical Response dataset). O segundo grupo, grupo de validação, contém o dataset BRCA-TCGA com 621 amostras, as 4142 amostras de câncer de mama da ferramenta Kmplot, as 17 amostras humanas primárias do subtipo BasL e sua informação sobre a geração, ou não, de tumores em camundongos imunosuprimidos e a análise de linhagens celulares (MF10A e HMLE). Para a análise dos dataset utilizamos o test-t pareado no pacote Limma da liguagem R, o algoritmo ARACNE para a inferência de regulons no dataset Clinical Response, a análise MRA-FET para definir os Reguladores Mestres para o fenótipo das bCSC e a análise GSEA para identificar o significado biológico de nosso achados nos diferentes datasets. RESULTADOS E DISCUSSÃO: Nós identificamos 12 TFs como reguladores mestres, com 9 deles formando duas redes altamente conectadas, uma positivamente relacionada ao fenótipo bCSC formada por SNAI2, TWIST, PRRX1, BNC2 e TBX5 com seus regulons, e definida aqui como a rede de transcrição mesenquimal, e uma rede correlacionada negativamente, formada por SCML4, ZNF831, SP140 e IKZF3, definida aqui como a rede de transcrição da resposta imune e totalmente desconhecida da literatura no contexto do câncer de mama. Embora ainda com fraca evidencia, ZEB1 para controlar as duas redes e ser responsável pela expressão de ALDH1 e dos 3 TFs restantes: ID4, HOXA5 e TEAD1. Como mostram seus nomes, e independente do dataset, do subtipo molecular ou da plataforma utilizada, a rede de transcrição mesenquimal, parece ser responsável pela manutenção do fenótipo de células tronco cancerígenas e a rede de transcrição da resposta imune pela resposta imune adaptativa ao tumor e a um bom prognóstico para as pacientes. CONCLUSÃO: Nós encontramos e descrevemos duas redes de fatores de transcrição que parecem controlar o fenótipo das bCSC, uma delas totalmente desconhecida até agora e relacionada a um bom prognóstico. Nosso achados possuem um claro potencial para uso clínico.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Winter, Jane. „Living with locally advanced rectal cancer : an exploration of the everydayness of living with rectal cancer“. Thesis, University of Southampton, 2010. https://eprints.soton.ac.uk/72288/.

Der volle Inhalt der Quelle

Annotation:

Advances in treatment and prolonged survival times mean that increasingly individuals are living with advanced cancer, yet services remain disease orientated. This thesis has documented the process of undertaking a longitudinal qualitative study to explore the everydayness of living with locally advanced rectal cancer. The study has identified how this can influence individual’s day to day lives when the focus of care moves away from cure, but prior to the transition to ‘end of life’ care. The aim was to obtain data in which to situate local service development based on those aspects which were accorded primacy by the participants. This interpretive study used a longitudinal qualitative approach which was informed by phenomenology. The philosophical works of Heidegger, Merleau Ponty and Van Manen were influential in this work which involved ten participants, with locally advanced rectal cancer. Successive interviews with ten individuals were undertaken over a two year period. The 38 interviews were analysed using a combination of frameworks offered by Miles and Huberman and Saldana. Individuals during much of this time concentrated on maintaining normality in their everyday lives. The drive for stasis and focus on day to day living allowed the individual to remain in the present and distance a future which was associated with illness and annihilation. Crucial to this was the ability to self-manage. This allowed space to create a self-definition of health. Uncertainty during this time was life affirming. Avoiding those who may challenge this, was desirable for as long as possible. As illness progressed there was an inverse relationship between the ‘boundness’ of the body and the ‘boundness’ of the individual. Insights from this study raise the need for further research and exploration of alternative models of supportive care whilst focusing on the wellness of individuals and self-management within their daily lives.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Nguyen, Nam, Siyoung Jang, Jacqueline Vock, Vincent Vinh-Hung, Alexander Chi, Paul Vos, Judith Pugh et al. „Feasibility of intensity-modulated and image-guided radiotherapy for locally advanced esophageal cancer“. BioMed Central, 2014. http://hdl.handle.net/10150/610350.

Der volle Inhalt der Quelle

Annotation:

BACKGROUND:In this study the feasibility of intensity-modulated radiotherapy (IMRT) and tomotherapy-based image-guided radiotherapy (IGRT) for locally advanced esophageal cancer was assessed.METHODS:A retrospective study of ten patients with locally advanced esophageal cancer who underwent concurrent chemotherapy with IMRT (1) and IGRT (9) was conducted. The gross tumor volume was treated to a median dose of 70Gy (62.4-75Gy).RESULTS:At a median follow-up of 14months (1-39 months), three patients developed local failures, six patients developed distant metastases, and complications occurred in two patients (1 tracheoesophageal fistula, 1 esophageal stricture requiring repeated dilatations). No patients developed grade 3-4 pneumonitis or cardiac complications.CONCLUSIONS:IMRT and IGRT may be effective for the treatment of locally advanced esophageal cancer with acceptable complications.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Bücher zum Thema "Locally advanced cervical cancer"

Ramaswamy, Govindan, Hrsg. Locally advanced non-small-cell lung cancer. Manhasset, NY: CMP United Business Media, 2004.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wellner, Ulrich. Locally advanced pancreatic head cancer – margin-positive resection or bypass? Freiburg: Universität, 2012.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Excellence, National Institute for Clinical. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer. London: National Institute for Clinical Excellence, 2003.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Dee, Baldwin, Hrsg. An Afrocentric approach to breast and cervical cancer early detection and screening: An educational program for undergraduate and advanced practice nursing students. Washington, DC: American Nurses Association, 1996.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Dee, Baldwin, und American Nurses Association, Hrsg. Faculty guidebook for an Afrocentric approach to breast and cervical cancer early detection and screening: An educational program for undergraduate and advanced practice nursing students. Washington, DC: American Nurses Association, 1996.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Izumi, Kouji, Hrsg. High-Risk Localized and Locally Advanced Prostate Cancer. MDPI, 2023. http://dx.doi.org/10.3390/books978-3-0365-8169-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Recent advances in locally advanced non-small-cell lung cancer. Manhasset, N.Y: CMPMedica, 2006.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Jocham, D. Therapeutic Options for Localized and Locally Advanced Prostate Cancer (Urologia Internationalis). S Karger Pub, 1998.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Moyad, Mark. Promoting Wellness for Advanced Prostate Cancer, 5th Edition: Your Locally Advanced to CRPC Empowerment Guide. Spry Publishing LLC, 2023.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Aigner, Karl Reinhard, und Frederick O. Stephens. Induction Chemotherapy: Integrated Treatment Programs for Locally Advanced Cancers. Springer, 2013.

Den vollen Inhalt der Quelle finden

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mehr Quellen

Buchteile zum Thema "Locally advanced cervical cancer"

Arimoto, Takahide. „Surgical Treatment of Locally Advanced Cervical Cancer“. In Comprehensive Gynecology and Obstetrics, 111–19. Singapore: Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-9396-3_8.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mabuchi, Seiji, Mahiru Kawano, Tomoyuki Sasano und Hiromasa Kuroda. „Management of Early-Stage and Locally Advanced Cervical Cancer“. In Handbook of Gynecology, 1–9. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-17002-2_34-1.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mabuchi, Seiji, Mahiru Kawano, Tomoyuki Sasano und Hiromasa Kuroda. „Management of Early-Stage and Locally Advanced Cervical Cancer“. In Handbook of Gynecology, 989–99. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-14881-1_34.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mabuchi, Seiji, Mahiru Kawano, Tomoyuki Sasano und Hiromasa Kuroda. „Management of Early-Stage and Locally Advanced Cervical Cancer“. In Handbook of Gynecology, 1–11. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-319-17002-2_34-2.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Mabuchi, Seiji, Mahiru Kawano, Tomoyuki Sasano und Hiromasa Kuroda. „Management of Early-Stage and Locally Advanced Cervical Cancer“. In Handbook of Gynecology, 845–52. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-17798-4_34.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Murakami, Isao, und Kyoko Tanaka. „Fertility-Sparing Treatment of Early and Locally Advanced Cervical Cancer“. In Comprehensive Gynecology and Obstetrics, 135–47. Singapore: Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-9396-3_10.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Höckel, Michael. „(Laterally) Extended Endopelvic Resection for the Treatment of Locally Advanced and Recurrent Cervical Cancer“. In Pelvic Cancer Surgery, 397–405. London: Springer London, 2015. http://dx.doi.org/10.1007/978-1-4471-4258-4_37.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Lim, Karen, Michael Milosevic, Kristy Brock und Anthony Fyles. „Image-Guidance in External Beam Planning for Locally Advanced Cervical Cancer“. In Gynecologic Radiation Therapy, 51–60. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68958-4_5.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Terai, Yoshito. „Sentinel Navigation Surgery for Local Advanced Cervical Cancer“. In Comprehensive Gynecology and Obstetrics, 149–61. Singapore: Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-9396-3_11.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Garton, G. R., T. O. Wilson, L. C. Hartmann, H. J. Long und K. C. Podratz. „Neo-Adjuvant M-VAC (Methotrexate, Vinblastine, Doxorubicin, Cisplatin) chemotherapy for locally advanced or metastatic cervical and vaginal cancer“. In Cancer Treatment An Update, 482–84. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_101.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Konferenzberichte zum Thema "Locally advanced cervical cancer"

Radojević, Marija Živković, Neda Milosavljević, Branislav Jeremić, Ivane Kiladze und Pavol Dubinsky. „Importance of HPV Typing in Predicting Response to Definitive Chemoradiation in Patients with Locally Advanced Cervical Cancer“. In 2024 IEEE 24th International Conference on Bioinformatics and Bioengineering (BIBE), 1–5. IEEE, 2024. https://doi.org/10.1109/bibe63649.2024.10820468.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

da Silva Dias, D., B. Gosalbez, L. Alves, P. Luz, T. Madureira, G. Vieira und I. Furtado. „EP276 Toxicity evaluation of locally advanced cervical cancer“. In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.337.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Aloui, Marwa, Ines Zemni, Houyem Mansouri, Souha Jaouadi, Nedia Boujelbene und Tarek Ben Dhieb. „#874 Locally advanced cervical cancer in young women“. In ESGO 2023 Congress. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/ijgc-2023-esgo.199.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Zemni, Ines, Marwa Aloui, Nadia Boujelbene, Saida Sakhri, Ines Zidi, Mohamed Ali Ayadi und Tarek Ben Dhiab. „397 Locally advanced cervical cancer in elderly women“. In ESGO 2024 Congress Abstracts. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/ijgc-2024-esgo.159.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Cantu, D., L. Gallardo-Alvardo, C. Perez-Plasencia, LA Herrera-Montalvo, O. Millan-Catalan und MD Perez-Montiel. „155 Tumor histology as prognostic in locally advanced cervical cancer“. In IGCS Annual 2019 Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-igcs.155.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Tan, David, Bradley J. Monk, Jitender Takyar, José David Hernández Chagüi, Takayuki Enomoto und Eric Pujade-Lauraine. „Comparison of locally advanced cervical cancer treatment guidelines in Asia“. In The 7th Biennial Meeting of Asian Society of Gynecologic Oncology. Korea: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology, 2021. http://dx.doi.org/10.3802/jgo.2021.32.s1.oc3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Salim, N., V. Nosov, D. Zvereva, P. Koposov, O. Novikova, A. Tedeeva, I. Trofimenko, E. Moskalets und N. Gromova. „EP371 Non-brachytherapy approach to treatment of locally advanced cervical cancer“. In ESGO Annual Meeting Abstracts. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/ijgc-2019-esgo.430.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Simões, Pedro, João Godinho, Luísa Leal-Costa, Mafalda Casa-Nova, Fernando Igreja, Gustavo Mendinhos, Rosa Madureira, Vanessa Monteiro, Vera Mendonça und José Passos-Coelho. „359 Induction chemotherapy for locally advanced cervical cancer – yay or nay?“ In ESGO SoA 2020 Conference Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-esgo.27.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Romero-Mendoza, Abraham, Carmen Cano-Flores, Melissa Mendoza-Santiago, Alejandra Niño-Herrera, Lenny Gallardo-Alvarado und David Cantu-de Leon. „447 Recurrence patterns according to time in locally advanced cervical cancer“. In ESGO SoA 2020 Conference Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-esgo.37.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Leary, A., B. Monk, J. Takyar, A. Nunes, JD Hernández Chagüi, K. Rabon-Stith und E. Pujade-Lauraine. „106 Comparison of locally advanced cervical cancer treatment guidelines in europe“. In ESGO 2021 Congress. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/ijgc-2021-esgo.5.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Berichte der Organisationen zum Thema "Locally advanced cervical cancer"

Hoeijmakers, Yvonne M. Cervical biopsy after chemoradiation for locally advanced cervical cancer to identify residual disease: a retrospective cohort study. Science Repository OÜ, März 2019. http://dx.doi.org/10.31487/j.jso.2019.01.001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Zou, Yihua, Fangqin Tong, Meng Guan, Chun Bi und Xia Wang. Efficacy and safety of Anti-angiogenesis combined with chemoradiotherapy in the treatment of locally advanced cervical cancer: A Meta-Analysis of Randomized Controlled Trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Juli 2022. http://dx.doi.org/10.37766/inplasy2022.7.0077.

Der volle Inhalt der Quelle

Annotation:

Review question / Objective: To Systematicly evaluate of the clinical efficacy and safety of the combination of anti-angiogenesis and simultaneous radiotherapy in the treatment of cervical cancer. Condition being studied: Locally advanced cervical cancer. We searched databases including PubMed, Cochrane Library, Embase, Web of Science CNKI, Wanfang, VIP and CBM, and the International Clinical Trial Registry Platform (ICTRP) and the Chinese Clinical Registry(ChiCTR) to collect the clinical studies about the randomized controlled trial (RCTS) of anti-angiogenic drugs (mainly Endu, apatinib and bevacizumab) combined with chemoradiotherapy in the treatment of cervical cancer. The time limit is from the establishment of the database to April 2022. RevMan 5.4 software was used to analyze the short-term efficacy and the incidence of adverse reactions.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Liu, Haonan, Xiaobing Qin und Zhengxiang Han. Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0089.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Viglianti, Benjamin, und Mark W. Dewhirst. Predicted Drug Concentration Distribution Using a Validated Finite Element Model in Locally Advanced Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, Juli 2004. http://dx.doi.org/10.21236/ada427760.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Schiff, Peter B. Trial Combining Taxol and Radiation Therapy for Treatment of Locally Advanced Breast Cancer. Phase 1. Fort Belvoir, VA: Defense Technical Information Center, Oktober 1996. http://dx.doi.org/10.21236/ada323556.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Braun, Rodney D. Use of Mitochondria-Specific Dye MKT-077 as a Radiosensitizer to Preoperatively Treat Locally Advanced Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, April 2008. http://dx.doi.org/10.21236/ada484788.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Carey, Lisa A. P53 Mutation Analysis to Predict Tumor Response in Patients Undergoing Neoadjuvant Treatment for Locally Advanced Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, Oktober 2004. http://dx.doi.org/10.21236/ada433971.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Klifa, Catherine. MRI Study of Uninvolved Breast Tissue for Patients With Locally Advanced Breast Cancer Undergoing Pre-Operative Chemotherapy. Fort Belvoir, VA: Defense Technical Information Center, August 2006. http://dx.doi.org/10.21236/ada477348.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!